Sapropterin dihydrochloride
盐酸沙丙蝶呤Oral BH4 therapy transitioning from the 2025 Commercial List (#2) into the 2026 NRDL Negotiated List (#42) with a published payment standard of ¥62.00 per 100mg tablet.
China Approval (NMPA)
Pending VerificationReimbursement catalog entries for this drug are verified from NHSA official PDFs. Individual NMPA registration certificate numbers (国药准字) and approval dates are queued for incremental verification.
National Reimbursement
Announced · Effective Jan 1, 2027- 2026 Edition Entry
- Negotiated #42 · Class B
- Agreement Period
- 2027-01-01 to 2028-12-31
- Payment Standard
- 62.00元(100mg/片)
- 2026 Payment Scope
- Restricted to hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4) deficiency.
- 限四氢生物蝶呤(BH4)缺乏症所导致的高苯丙氨酸血症(HPA)。
Commercial Insurance List
2025 Only (Not in 2026)Previously listed in the 2025 Commercial Insurance Innovative Drug List (#2). Graduated into the 2026 Basic NRDL (#42).
Approved Products, Dosage Forms & Approval Numbers
0 verified NMPA recordsChange Timeline
- (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026
2026 NRDL · Added to Negotiated List
Newly added to 2026 NRDL Negotiated List (#42, Class B, ¥62.00 per 100mg tablet) for BH4-deficiency HPA; transitioned from the 2025 Commercial List (#2).
Chinese original: 由2025版商保创新药目录(第2项)转入2026版基本医保谈判药品第42项(乙类,62.00元/100mg片),限BH4缺乏症所致HPA。
NHSA · PDF p.120Verified 2026-11-20 - (2026-01-01)Commercial List· Catalog published: Dec 7, 2025
2025 Commercial List · Removed in 2026 Edition (#2)
Listed in 2025 Commercial List (#2) for BH4-responsive HPA; graduated into the 2026 basic NRDL Negotiated List (#42).
Chinese original: 适用于对本品治疗有反应的四氢生物蝶呤(BH4)缺乏症所导致的高苯丙氨酸血症(HPA),可用于成人及4岁以上儿童。
NHSA · PDF p.2Verified 2026-11-20
Verified Names & Aliases
Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.
Primary Sources for This Record
- NHSAPublished 2026-11-14国家基本医疗保险、生育保险和工伤保险药品目录(2026年)Retrieved 2026-11-20
- NHSAPublished 2025-12-07商业健康保险创新药品目录(2025年)Retrieved 2026-11-20 · 医保发〔2025〕33号附件